Lannett Company Expecting FDA Decision (LCI)

Shares of Lannett Company LCI have been trending higher in recent trading sessions as the company is expecting NDA approval from the FDA for its morphine sulfate oral solution with a re-launch anticipated in early 2011. During Monday's session, LCI has risen 2.02% to $5.32. Volume has been a little heavier than average with 270,000 shares trading hands. Lannett Company, Inc. (Lannett) develops, manufactures, markets and distributes generic versions of branded pharmaceutical products. All of its products manufactured and/or sold are prescription products.